Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia

Biological Psychiatry

Volumn 56, Issue 6, 2004, Pages 441-446

  Kremer, Ilana ^a   Vass, Agnes ^a,b   Gorelik, Ielena ^a   Bar, Gali ^b   Blanaru, Monica ^a   Javitt, Daniel C ^d   Heresco Levy, Uriel ^b,c  

^a HAEMEK MEDICAL CENTER   (Israel)

^b HERZOG HOSPITAL   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Atypical antipsychotics; conventional neuroleptics; lamotrigine; schizophrenia

Indexed keywords

ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORAL HYDRATE; GLUTAMIC ACID; LAMOTRIGINE; NEUROLEPTIC AGENT; PLACEBO; TRIHEXYPHENIDYL;

ADJUVANT CHEMOTHERAPY; ADULT; AGITATION; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSOMNIA; LIVER TOXICITY; MALE; NEPHROTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AMINO ACIDS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIAZINES;

EID: 4444352847     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.06.029     Document Type: Article

References (39)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed 1994 American Psychiatric Association Washington, DC
2. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, A. Cappiello, J.H. Krystal Attenuation of neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists Arch Gen Psychiatry 57 2000 270 276
3. N.C. Andreasen Scale for the Assessment of Negative Symptoms (SANS) 1981 University of Iowa Iowa City, Iowa
4. R.J. Baldessarini, J.C. Kando, F. Centorrino Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay Am J Psychiatry 152 1995 1038 1044
5. F.M. Benes, S. Berretta GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder Neuropsychopharmacology 25 2001 1 27
6. C.L. Bowden, J.R. Calabrese, G. Sachs, N.Y. Lakshmi, A. Shaheen, M Honipland Lamictal 606 Study Group A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder Arch Gen Psychiatry 60 2003 392 400
7. A.H. Burstein Evaluation of new drugs: Lamotrigine Pharmacotherapy 15 1995 129 143
8. J.R. Calabrese, C.L. Bowden, G.S. Sachs, G.A. Asher, E. Monaghan, G.B Rudd Lamictal 602 Study Group A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression J Clin Psychiatry 60 1999 79 88
9. J.R. Calabrese, C.L. Bowden, G. Sachs, L.N. Yatham, K. Behnke, O.P Mehtonen Lamictal 602 Study Group A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder J Clin Psychiatry 64 2003 1013 1024
10. J.R. Calabrese, J.R. Sullivan, C.L. Bowden, T. Suppes, G.F. Goldberg, G.S. Sachs Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management J Clin Psychiatry 63 2002 1012 1019
11. J.R. Calabrese, T. Suppes, C.L. Bowden, G.S. Sachs, A.C. Swann, S.L McElroy Lamictal 602 Study Group A double-blind, placebo-controlled prophylaxis study of lamotrigine in rapid-cycling bipolar disorder J Clin Psychiatry 61 2000 841 850
12. A. Carlsson, N. Waters, S. Holm-Waters, J. Tedroff, M. Nilsson, M.L. Carlsson Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence Annu Rev Pharmacol Toxicol 41 2001 237 260
13. T.W. Carpenter Jr, R. Kurz, B. Kirkpatrick, T.H.E. Hanlon, A.T. Summerfelt, R.W Buchanan Carbamazepine maintenance treatment in outpatient schizophrenics Arch Gen Psychiatry 48 1991 69 72
14. D.E. Casey, D.G. Daniel, A.A. Wassef, K.A. Tracy, P. Wozniak, K.W. Sommerville Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia Neuropsychopharmacology 28 2003 182 192
15. L. Citrome, J. Levine, B. Allingham Utilization of valproate: Extent of inpatient use in the New York State Office of Mental Health Psychiatr Q 69 1998 283 300
16. J. Cohen Statistical Power Analysis for the Behavioral Sciences 2nd ed 1998 Erlbaum Hillsdale, NJ
17. S.I. Deutsch, R.B. Rosse, B.L. Schwartz, J. Mostropaolo A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications Clin Neuropharmacol 24 2001 43 49
18. M. Dose, R. Hellwweg, A. Yassouridis, M. Theison, H.M. Emrich Combined treatment of schizophrenic psychoses with haloperidol and valproate Pharmacopsychiatry 31 1998 122 125
19. S.M. Dursun, J.F.W. Deakin Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study J Psychopharmacol 15 2001 297 301
20. S.M. Dursun, D. McIntosh, H. Milliken Clozapine plus lamotrigine in treatment-resistant schizophrenia Arch Gen Psychiatry 56 1999 950
21. W. Guy Assessment Manual for Psychopharmacology rev. ed(DHEW Pub. No. ADM 76-338) 1976 U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Rockville, MD
22. M. Hamilton A rating scale for depression J Neurol Neurosurg Psychiatry 23 1960 56 62
23. U. Heresco-Levy Amino acid transmitter systems in schizophrenia and other psychotic disorders H. D'haenen J.A. den Boer P. Willner editors Biological Psychiatry 2002 Wiley London 587 600
24. S.R. Kay, A. Fiszbein, L.A. Opler The Positive and Negative Syndrome Scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
25. J.H. Krystal, A. Anand, B. Moghaddam Effects of NMDA receptor antagonists: Implications for the pathophysiology of schizophrenia Arch Gen Psychiatry 59 2002 663 664
26. D.M. Labiner Lamotrigine and rash: Scratching beneath the surface J Clin Psychiatry 63 2002 1010 1011
27. A.C. Lahti, M.A. Weiler, B.A. Tamara Michaelidis, A. Parwani, C.A. Tamminga Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 25 2001 455 467
28. M.J. Leach, M.G. Baxter, M.A. Critchley Neurochemical and behavioural aspects of lamotrigine Epilepsia 32 suppl 2 1991 S4 S8
29. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, K. Elgen The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand 334 suppl 1987 1 100
30. B. Moghaddam, B.W. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats Science 281 1998 1349 1352
31. B. Moghaddam, B.W. Adams, A. Verma, D. Daly Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci 17 1997 2921 2927
32. J.W. Olney, J.W. Newcomer, N.B. Farber Attenuation of the neuropsychiatric effects of ketamine with lamotrigine [reply] Arch Gen Psychiatry 59 2002 467 468
33. J.E. Overall, D.E. Gorham The Brief Psychiatric Rating Scale Psychol Rep 10 1961 799 812
34. Physicians' Desk Reference Lamictal (lamotrigine) 2002 Medical Economics Montvale NJ 1567-1574
35. G. Saba, G. Dumortier, K. Kalalou, R. Benadhira, K. Degrassat, J. Glikman, D. Januel Lamotrigine and clozapine combination in refractory schizophrenia: Three cases J Neuropsychiatry Clin Neurosci 14 2002 86
36. G.M. Simpson, J.W.S. Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand 212 1970 11 19
37. D. Smith, G. Baker, G. Davies, M. Dewey, D.W. Chadwick Outcomes of add-on treatment with lamotrigine in partial epilepsy Epilepsia 34 1993 312 322
38. S. Tekin, C. Aykut-Bingol, T. Tanridag, S. Aktan Antiglutamatergic therapy in Alzheimer's disease - effects of lamotrigine J Neural Transm 105 1998 295 303
39. J. Tiihonen, T. Hallikainen, O.-P. Ryynänen, E. Repo-Tiihonen, I. Kotilainen, M Eronen Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial Biol Psychiatry 54 2003 1 6